GlaxoSmithKline has
confirmed that its Tafinlar
(dabrafenib mesilate) has been
registered for the treatment of
metastatic melanoma in Australia.
It’s TGA approved for patients
with BRAF V600 mutation positive
melanoma that is unresectable or
metastatic.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Sep 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Sep 13
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.